FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today!

About | Sample | Privacy

Vasella: 'Teva is better than we are'

Tools

Novartis CEO Daniel Vasella has a knack for the quotable quote. Here's the latest: "Teva is better than we are, and that's hard to take."

You'll recall that Vasella has been talking a lot about diversification lately, what with Novartis beefing up its optical biz with a big chunk of Alcon and pushing to expand its vaccine operations. Well, the company's generics unit, Sandoz, is another big component of that diversification strategy. And Vasella isn't satisfied with Sandoz's performance. Teva is bigger, it's vertically integrated--and it's been outpacing Sandoz on various key benchmarks. In a glass-half-full take on the difference, Vasella told the WSJ Health Blog that Teva's successes could serve as inspiration. "It is good to look at how we could be better," he said.

- read the Health Blog post

Related Articles:
Novartis' Daniel Vasella--CEO Pay
Vasella touts Novartis' diversification
Novartis taps new U.S. pharma chief
CEO: Novartis plans big restructuring
Novartis pledges $39B for Alcon

More stories about Novartis   Generics   Daniel Vasella   Teva Pharmaceutical  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 29 + 1?
To combat spam, please solve the math question above.